0
USD ▼
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
End Stage Renal Disease Market by Treatment Modality, End User, Access Type - Global Forecast to 2030- Product Image
End Stage Renal Disease Market by Treatment Modality, End User, Access Type - Global Forecast to 2030- Product Image
Sale

End Stage Renal Disease Market by Treatment Modality, End User, Access Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5337854
UP TO EUR$697USDGBP OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior decision-makers navigating the end stage renal disease market face a complex mix of rising clinical demands and rapid technological change. As treatment models evolve and policy shifts impact costs and care delivery, stakeholders must act decisively to secure operational resilience and future-ready strategies.

Market Snapshot: End Stage Renal Disease Market

The end stage renal disease market advanced from USD 53.09 billion in 2024 to USD 61.04 billion in 2025, with projections toward USD 121.83 billion by 2030 at a CAGR of 14.84%. Demand is fueled by clinical necessity, increasing prevalence of chronic kidney failure, and ongoing dependence on resource-intensive treatments. The market landscape is shaped by innovative care models, shifting reimbursement strategies, and adaptive supply chains—creating both operational pressures and growth opportunities for global healthcare organizations.

Scope & Segmentation

This comprehensive analysis evaluates the full spectrum of care models, geographies, and provider strategies within the end stage renal disease market.

  • Treatment Modalities: Hemodialysis (home and incenter), Peritoneal Dialysis (continuous ambulatory and continuous cycling), and Transplantation (deceased and living donor approaches).
  • End Users: Dialysis centers, home care settings, and hospitals, each defining unique patient pathways and operational dynamics.
  • Access Types: Arteriovenous fistula, central venous catheter, and synthetic graft options—each influencing clinical outcomes and care continuity.
  • Regional Scope: Americas, Europe, Middle East, Africa, and Asia-Pacific, encompassing advanced and emerging healthcare systems.
  • Key Market Participants: Fresenius Medical Care AG & Co. KGaA, DaVita Inc., Baxter International Inc., B. Braun Melsungen AG, Nipro Corporation, NxStage Medical, U.S. Renal Care, Satellite Healthcare, Dialysis Clinic, and Jafron Biomedical.

Technology adoption, such as remote monitoring and wearable dialysis, as well as integration of personalized and precision medicine approaches, play critical roles in market differentiation and patient engagement across all segments.

Key Takeaways for Senior Leaders

  • Adoption of home-based treatment options is on the rise, allowing providers to address patient preferences while optimizing operational costs and care quality.
  • Digital health, telehealth, and real-time remote monitoring foster early intervention and improved adherence, gifting providers more effective touchpoints throughout the care continuum.
  • Collaborations among device manufacturers, pharmaceutical companies, and healthcare systems accelerate access to next-generation therapies and facilitate best practice sharing.
  • Integrated, multidisciplinary care models—often supported by value-based reimbursement structures—are helping drive improved clinical and operational outcomes.
  • Providers that efficiently combine clinical excellence with streamlined supply chains gain the agility needed to adapt to evolving regulatory and technology landscapes.

Tariff Impact and Supply Chain Shifts

Recent U.S. tariffs on imported dialysis equipment have increased supply chain costs, compelling providers to re-evaluate sourcing, enter long-term contracts, and pursue local manufacturing partnerships. While larger players may consolidate market share through these investments, smaller organizations could struggle with procurement flexibility. The resulting market environment intensifies the need for outcome-based agreements and innovative cost-sharing models, placing a premium on supply chain agility and financial stewardship.

Methodology & Data Sources

This report employs a rigorous, multistep research process. An extensive review of peer-reviewed journals, regulatory filings, company reports, and industry papers forms the secondary research foundation. These insights are augmented through interviews with industry leaders, clinical experts, and payer organizations, as well as quantitative validation from shipment, procedure, and reimbursement data sets.

Why This Report Matters

  • Delivers actionable, segmented insights for aligning your organization’s investment, care delivery, and technology strategies with prevailing and future market dynamics.
  • Equips decision-makers with region-specific policy and reimbursement intelligence crucial for expanding operational reach and mitigating regulatory risk.
  • Highlights competitive strategies and innovation pathways to support robust decision-making in resource allocation and partnership development.

Conclusion

The end stage renal disease market is transforming as new therapies, supply chain models, and care frameworks emerge. Stakeholders able to harness data, foster strategic collaborations, and swiftly adapt to policy change will be best positioned for long-term leadership in this complex landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. End Stage Renal Disease Market, by Treatment Modality
8.1. Introduction
8.2. Hemodialysis
8.2.1. Home
8.2.2. Incenter
8.3. Peritoneal Dialysis
8.3.1. Continuous Ambulatory Peritoneal Dialysis
8.3.2. Continuous Cycling Peritoneal Dialysis
8.4. Transplant
8.4.1. Deceased Donor
8.4.2. Living Donor
9. End Stage Renal Disease Market, by End User
9.1. Introduction
9.2. Dialysis Centers
9.3. Home Care Settings
9.4. Hospitals
10. End Stage Renal Disease Market, by Access Type
10.1. Introduction
10.2. Arteriovenous Fistula
10.3. Central Venous Catheter
10.4. Synthetic Graft
11. Americas End Stage Renal Disease Market
11.1. Introduction
11.2. United States
11.3. Canada
11.4. Mexico
11.5. Brazil
11.6. Argentina
12. Europe, Middle East & Africa End Stage Renal Disease Market
12.1. Introduction
12.2. United Kingdom
12.3. Germany
12.4. France
12.5. Russia
12.6. Italy
12.7. Spain
12.8. United Arab Emirates
12.9. Saudi Arabia
12.10. South Africa
12.11. Denmark
12.12. Netherlands
12.13. Qatar
12.14. Finland
12.15. Sweden
12.16. Nigeria
12.17. Egypt
12.18. Turkey
12.19. Israel
12.20. Norway
12.21. Poland
12.22. Switzerland
13. Asia-Pacific End Stage Renal Disease Market
13.1. Introduction
13.2. China
13.3. India
13.4. Japan
13.5. Australia
13.6. South Korea
13.7. Indonesia
13.8. Thailand
13.9. Philippines
13.10. Malaysia
13.11. Singapore
13.12. Vietnam
13.13. Taiwan
14. Competitive Landscape
14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Analysis
14.3.1. Fresenius Medical Care AG & Co. KGaA
14.3.2. DaVita Inc.
14.3.3. Baxter International Inc.
14.3.4. B. Braun Melsungen AG
14.3.5. Nipro Corporation
14.3.6. NxStage Medical, Inc.
14.3.7. U.S. Renal Care, Inc.
14.3.8. Satellite Healthcare, Inc.
14.3.9. Dialysis Clinic, Inc.
14.3.10. Jafron Biomedical Co., Ltd.
15. ResearchAI
16. ResearchStatistics
17. ResearchContacts
18. ResearchArticles
19. Appendix
List of Figures
FIGURE 1. END STAGE RENAL DISEASE MARKET MULTI-CURRENCY
FIGURE 2. END STAGE RENAL DISEASE MARKET MULTI-LANGUAGE
FIGURE 3. END STAGE RENAL DISEASE MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. END STAGE RENAL DISEASE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. END STAGE RENAL DISEASE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. END STAGE RENAL DISEASE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY INCENTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS AMBULATORY PERITONEAL DIALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS CYCLING PERITONEAL DIALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DECEASED DONOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY LIVING DONOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ARTERIOVENOUS FISTULA, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CENTRAL VENOUS CATHETER, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY SYNTHETIC GRAFT, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 41. CANADA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 42. CANADA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 43. CANADA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 44. CANADA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 45. CANADA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. CANADA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 47. MEXICO END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 48. MEXICO END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 49. MEXICO END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 50. MEXICO END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 51. MEXICO END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 52. MEXICO END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 54. BRAZIL END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 55. BRAZIL END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 56. BRAZIL END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 65. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 66. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 67. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 68. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 69. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 71. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 72. UNITED KINGDOM END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 73. UNITED KINGDOM END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 74. UNITED KINGDOM END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 75. UNITED KINGDOM END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 76. UNITED KINGDOM END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. UNITED KINGDOM END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 78. GERMANY END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 79. GERMANY END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 80. GERMANY END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 81. GERMANY END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 82. GERMANY END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. GERMANY END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 84. FRANCE END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 85. FRANCE END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 86. FRANCE END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 87. FRANCE END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 88. FRANCE END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. FRANCE END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 90. RUSSIA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 91. RUSSIA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 92. RUSSIA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 93. RUSSIA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 94. RUSSIA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. RUSSIA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 96. ITALY END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 97. ITALY END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 98. ITALY END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 99. ITALY END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 100. ITALY END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 101. ITALY END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 102. SPAIN END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 103. SPAIN END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 104. SPAIN END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 105. SPAIN END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 106. SPAIN END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. SPAIN END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 108. UNITED ARAB EMIRATES END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 109. UNITED ARAB EMIRATES END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 110. UNITED ARAB EMIRATES END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 111. UNITED ARAB EMIRATES END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 112. UNITED ARAB EMIRATES END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. UNITED ARAB EMIRATES END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 114. SAUDI ARABIA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 115. SAUDI ARABIA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 116. SAUDI ARABIA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 117. SAUDI ARABIA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 118. SAUDI ARABIA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. SAUDI ARABIA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 120. SOUTH AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 121. SOUTH AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 122. SOUTH AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 123. SOUTH AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 126. DENMARK END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 127. DENMARK END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 128. DENMARK END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 129. DENMARK END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 130. DENMARK END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. DENMARK END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 132. NETHERLANDS END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 133. NETHERLANDS END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 134. NETHERLANDS END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 135. NETHERLANDS END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 136. NETHERLANDS END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 138. QATAR END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 139. QATAR END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 140. QATAR END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 141. QATAR END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 142. QATAR END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 143. QATAR END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 144. FINLAND END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 145. FINLAND END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 146. FINLAND END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 147. FINLAND END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 148. FINLAND END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. FINLAND END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 150. SWEDEN END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 151. SWEDEN END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 152. SWEDEN END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 153. SWEDEN END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 154. SWEDEN END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. SWEDEN END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 156. NIGERIA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 157. NIGERIA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 158. NIGERIA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 159. NIGERIA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 160. NIGERIA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. NIGERIA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 162. EGYPT END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 163. EGYPT END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 164. EGYPT END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 165. EGYPT END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 166. EGYPT END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. EGYPT END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 168. TURKEY END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 169. TURKEY END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 170. TURKEY END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 171. TURKEY END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 172. TURKEY END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. TURKEY END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 174. ISRAEL END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 175. ISRAEL END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 176. ISRAEL END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 177. ISRAEL END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 178. ISRAEL END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. ISRAEL END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 180. NORWAY END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 181. NORWAY END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 182. NORWAY END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 183. NORWAY END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 184. NORWAY END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. NORWAY END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 186. POLAND END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 187. POLAND END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 188. POLAND END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 189. POLAND END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 190. POLAND END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. POLAND END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 192. SWITZERLAND END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 193. SWITZERLAND END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 194. SWITZERLAND END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 195. SWITZERLAND END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 196. SWITZERLAND END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. SWITZERLAND END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 198. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 199. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 200. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 201. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 202. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 204. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 205. CHINA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 206. CHINA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 207. CHINA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 208. CHINA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 209. CHINA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. CHINA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 211. INDIA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 212. INDIA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 213. INDIA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 214. INDIA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 215. INDIA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. INDIA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 217. JAPAN END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 218. JAPAN END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 219. JAPAN END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 220. JAPAN END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 221. JAPAN END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. JAPAN END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 223. AUSTRALIA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 224. AUSTRALIA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 225. AUSTRALIA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 226. AUSTRALIA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 227. AUSTRALIA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. AUSTRALIA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 229. SOUTH KOREA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 230. SOUTH KOREA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 231. SOUTH KOREA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 232. SOUTH KOREA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 233. SOUTH KOREA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. SOUTH KOREA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 235. INDONESIA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 236. INDONESIA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 237. INDONESIA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 238. INDONESIA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 239. INDONESIA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. INDONESIA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 241. THAILAND END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 242. THAILAND END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 243. THAILAND END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 244. THAILAND END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 245. THAILAND END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. THAILAND END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 247. PHILIPPINES END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 248. PHILIPPINES END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 249. PHILIPPINES END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 250. PHILIPPINES END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 251. PHILIPPINES END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. PHILIPPINES END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 253. MALAYSIA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 254. MALAYSIA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 255. MALAYSIA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 256. MALAYSIA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 257. MALAYSIA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. MALAYSIA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 259. SINGAPORE END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 260. SINGAPORE END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 261. SINGAPORE END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 262. SINGAPORE END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 263. SINGAPORE END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. SINGAPORE END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 265. VIETNAM END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 266. VIETNAM END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 267. VIETNAM END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 268. VIETNAM END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 269. VIETNAM END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 270. VIETNAM END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 271. TAIWAN END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 272. TAIWAN END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 273. TAIWAN END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2030 (USD MILLION)
TABLE 274. TAIWAN END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 275. TAIWAN END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. TAIWAN END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2030 (USD MILLION)
TABLE 277. END STAGE RENAL DISEASE MARKET SHARE, BY KEY PLAYER, 2024
TABLE 278. END STAGE RENAL DISEASE MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Sample File DOWNLOAD NOW

Companies Mentioned

The companies profiled in this End Stage Renal Disease market report include:
  • Fresenius Medical Care AG & Co. KGaA
  • DaVita Inc.
  • Baxter International Inc.
  • B. Braun Melsungen AG
  • Nipro Corporation
  • NxStage Medical, Inc.
  • U.S. Renal Care, Inc.
  • Satellite Healthcare, Inc.
  • Dialysis Clinic, Inc.
  • Jafron Biomedical Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages199
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 61.04 Billion
Forecasted Market Value ( USD ) by 2030 $ 121.83 Billion
Compound Annual Growth Rate14.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

End-Stage Renal Disease - Global Strategic Business Report - Product Image

End-Stage Renal Disease - Global Strategic Business Report

  • Report
  • 89 Pages
  • Global
From
EUR$5,850USDGBP
End-Stage Kidney Disease - Pipeline Insight, 2025 - Product Image

End-Stage Kidney Disease - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
EUR$2,000USDGBP
Diabetic Nephropathy Treatment Market by Treatment Type, Distribution Channel, Route Of Administration, Disease Stage, Patient Population - Global Forecast to 2030 - Product Image

Diabetic Nephropathy Treatment Market by Treatment Type, Distribution Channel, Route Of Administration, Disease Stage, Patient Population - Global Forecast to 2030

  • Report
  • 190 Pages
  • Global
From
EUR$3,545USDGBP
EUR$3,939USDGBP
Alport Syndrome Market by Treatment Type, End User, Distribution Channel, Patient Age Group, Disease Stage, Insurance Type - Global Forecast to 2030 - Product Image

Alport Syndrome Market by Treatment Type, End User, Distribution Channel, Patient Age Group, Disease Stage, Insurance Type - Global Forecast to 2030

  • Report
  • 181 Pages
  • Global
From
EUR$3,545USDGBP
EUR$3,939USDGBP
Renal Failure Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Renal Failure Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 183 Pages
  • Global
From
EUR$3,825USDGBP
EUR$4,500USDGBP

About the End Stage Renal Disease Drug Market

End Stage Renal Disease (ESRD) Drug market is a subset of the larger Liver and Kidney Disorders Drugs market. ESRD drugs are used to treat patients with advanced kidney failure, who require dialysis or a kidney transplant. These drugs are used to reduce the symptoms of kidney failure, such as anemia, high blood pressure, and bone disease. They also help to reduce the risk of complications from dialysis and kidney transplantation. Common ESRD drugs include erythropoietin, calcitriol, and iron supplements. The ESRD Drug market is highly competitive, with many companies offering a variety of products. Major players in the market include Amgen, AstraZeneca, Baxter, Fresenius Medical Care, and Novartis. Other companies in the market include AbbVie, Allergan, Daiichi Sankyo, and Merck. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.
This website uses cookies to ensure you get the best experience. Learn more